AccessDx Laboratory
AccessDx Laboratory is a CLIA-certified molecular diagnostic laboratory offering pharmacogenomics, hereditary cancer, and infectious disease testing to US healthcare providers, health systems, and long-term/post-acute care facilities, operating within the Aranscia precision medicine portfolio.
- Company typePrivate
- Founded2016
- HeadquartersHouston, United States
- Headcount251–500
- GTM typeB2B
- OfferingServices
What AccessDx Laboratory does
AccessDx Laboratory is a CLIA-certified, CAP-accredited, and NYSDOH-approved molecular diagnostic laboratory headquartered in Houston, Texas, operating as a subsidiary of the Aranscia precision-medicine holding company. The lab provides pharmacogenomics (PGx), hereditary cancer genomics, and infectious disease molecular testing to healthcare providers across the United States, claiming more than 2,000 active clients and a cumulative volume exceeding 2 million molecular diagnostic tests. Compliance posture is reinforced by HIPAA and FDA standards adherence, with company leaders holding advisory roles at standards-setting bodies including CPIC, PGRN, NCPDP, PharmVar, ClinGen, and AMP.
The testing portfolio centers on two PGx panels — a 37+ gene Comprehensive Panel and a 20-gene Focused Panel — both delivered with actionable drug-gene interaction guidance derived from CPIC, FDA, and DPWG standards across 16+ therapeutic areas. The lab's panel architecture is designed to detect complex structural variations and rare ethno-specific variants per AMP Tier 1 and Tier 2 guidance, with single-gene DPYD testing added for chemotherapy safety. Adjacent offerings include a 33-gene hereditary cancer panel and a broad multiplex RT-PCR infectious disease menu (respiratory pathogen, GI pathogen, UTI PROx with culture and antimicrobial susceptibility, wound, nail, COVID-19, flu, and COVID+flu combo). Results are delivered through the AccessDx Provider Portal and Patient Portal and integrated with PointClickCare, 2bPrecise, and YouScript clinical decision support within the broader Aranscia stack.
AccessDx generates revenue primarily through per-test clinical laboratory fees with multiple billing routes — client billing at approximately $350 per PGx panel, third-party insurance billing, and patient-pay options. The go-to-market is enterprise field sales, targeting provider groups, hospitals and health systems, long-term and post-acute care facilities, pharmacies, and consulting pharmacists across therapeutic segments including behavioral health, cardiology, primary care, and oncology. Test ordering is enabled through the provider portal, paper requisition forms, and platform integrations with PointClickCare, 2bPrecise, and YouScript, which double as distribution channels for embedded clinical workflows rather than as standalone software revenue.
AccessDx Laboratory firmographics
Firmographics- Name
- AccessDx Laboratory
- Legal name
- AccessDx Laboratory, LLC
- Website
- https://accessdxlab.com
- Company type
- Private
- Founded year
- 2016
- Operating status
- Operating
- Headcount range
- 251–500 employees
- Short description
- AccessDx Laboratory is a CLIA-certified molecular diagnostic laboratory offering pharmacogenomics, hereditary cancer, and infectious disease testing to US healthcare providers, health systems, and long-term/post-acute care facilities, operating within the Aranscia precision medicine portfolio.
- Ownership category
- akta.pro rank
AccessDx Laboratory industry classification
Industry- Product category
- Molecular Diagnostics
- NAICS
- Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215), Medical and Diagnostic Laboratories (62151)
- SIC
- Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- Pharmacogenomics (PGx) Decision Support (HLAAANAB)
- akta.pro secondary industries
- Companion Diagnostics (CDx) Development & Commercialization (HLAAANAC), Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays) (HLAAALAL), Companion Diagnostics (CDx) & Therapy Selection Assays (HLAAALAF), Toxicology & Therapeutic Drug Monitoring Laboratories (HLAFAMAF)
Keywords
Where AccessDx Laboratory is headquartered
LocationHeadquarters
- HQ city
- Houston
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
AccessDx Laboratory business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales, Others
Revenue model
- Clinical Laboratory Testing Services: AccessDx Laboratory generates revenue through clinical laboratory testing services including pharmacogenomics (PGx) testing, hereditary cancer genomics testing, and infectious disease molecular diagnostic testing. The company offers multiple billing options including client billing ($350), insurance billing, and patient pay options.
- Clinical Decision Support Integration: Revenue derived from providing PGx results integrated into clinical decision support tools accessible through the AccessDx laboratory portal or EMR integrations via 2bPrecise platform and YouScript clinical decision support software.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| One time/ perpetual license | Pay-as-you-go | Client Bill pricing for PGx testing |
| Transaction based/ take rate | Pay-as-you-go | Insurance billing option |
| Unit Pricing | Pay-as-you-go | Patient pay option |
Go-to-market motion1 record
Distribution channels4 records
Marketing channels7 records
AccessDx Laboratory product offering
Product offeringCore offering
AccessDx Laboratory operates as a CLIA-certified, CAP-accredited, and NYSDOH-approved molecular diagnostic laboratory delivering pharmacogenomics (PGx) testing, hereditary cancer genomics testing, and a portfolio of multiplex RT-PCR infectious disease panels (respiratory, gastrointestinal, urinary, wound, nail, COVID-19, and influenza). Testing is offered to healthcare providers through a web-based provider portal, paper requisitions, and integrations with PointClickCare, 2bPrecise, and YouScript clinical decision support.
Product overview
AccessDx Laboratory offers a portfolio of precision medicine and molecular diagnostic solutions. The core offerings include pharmacogenomics (PGx) testing through two panel options—the Comprehensive Panel (37+ genes) and Focused Panel (20 genes)—along with single-gene DPYD testing for chemotherapy safety. Hereditary Cancer Testing covers 33 genes for cancer risk assessment. The infectious disease portfolio includes RT-PCR molecular diagnostic tests for COVID-19, influenza, gastrointestinal pathogens, respiratory pathogens, urinary tract infections, nail infections, and wound infections. The Medication Safety Program for LTPACs bundles PGx testing with clinical decision support for long-term care facilities. Access is provided through provider and patient web portals, with integrations into PointClickCare, YouScript, and 2bPrecise platforms.
Differentiator
Problem solved
Functional benefit
Products and services
- AccessDx PGx Profile - Comprehensive Panel A multispecialty pharmacogenomics panel for healthcare providers covering 37+ genes and 16+ therapeutic areas, with actionable drug-gene interaction guidance grounded in CPIC, FDA, and DPWG standards to inform prescribing across specialties.
- AccessDx PGx Profile - Focused Panel A focused pharmacogenomics panel including 20 high-evidence genes with actionable guidance and HLA risk alleles for targeted medication optimization across multiple specialties.
- DPYD Testing A single-gene pharmacogenomic test for DPD enzyme deficiency used to identify oncology patients at risk of severe adverse reactions to capecitabine (Xeloda) or fluorouracil (5-FU) chemotherapy.
- Hereditary Cancer Testing A hereditary cancer genomics panel covering 33 genes known to harbor variants linked to common hereditary cancer syndromes, aimed at detecting causative variants in patients with personal or family cancer history.
- COVID-19 PCR Testing An FDA-compliant RT-PCR test for rapid SARS-CoV-2 identification enabling faster diagnosis and management of COVID-19 infection.
- COVID-19 + Flu Combo Testing A combined RT-PCR test that simultaneously detects SARS-CoV-2, Influenza A, and Influenza B virus strains to distinguish COVID-19 from influenza infections.
- Influenza A+B Testing An RT-PCR test for simultaneous detection of both Influenza A and B virus strains to support diagnosis and management of flu-like illnesses.
- Respiratory Pathogen Panel (RPP) Testing A comprehensive multiplex RT-PCR test detecting multiple viral and bacterial respiratory pathogens to support diagnosis and management of respiratory infections.
- Gastrointestinal Pathogen Panel Testing A comprehensive multiplex RT-PCR test detecting enteropathogenic viruses, bacteria, parasites, and antibiotic drug resistance genes for diagnosis and management of gastrointestinal infections.
- UTI PROx Panel A test combining multiplex RT-PCR with pathogen culture and antimicrobial susceptibility testing to detect and characterize uropathogens and resistance gene profiles for difficult, repeated, or persistent urinary tract infections.
- Wound Pathogen Panel Testing A comprehensive multiplex RT-PCR test detecting fungal, bacterial wound infections, and antibiotic resistance genes for precise diagnosis and treatment of wound infections.
- Nail Pathogen Panel Testing A multiplex RT-PCR test detecting fungal and bacterial nail infections and antibiotic resistance genes to support precise diagnosis and treatment of nail infections.
- Medication Safety Program for LTPACs A bundled precision medicine program for long-term and post-acute care facilities that combines PGx testing, adverse drug interaction risk assessments, clinical decision support, and quality improvement tools to reduce readmissions, ED visits, falls, and polypharmacy.
Quantifiable outcome
- 52% reduction in readmissions in long-term care settings
- +8 more outcomes
Companies that use AccessDx Laboratory
Customer profileNamed customers2 records
Segments7 records
Ideal customer profiles3 records
AccessDx Laboratory technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration3 records
AI capability4 records
Feature7 records
AccessDx Laboratory partnerships and signals
Strategic signalPartnerships
Nine partnerships are on record, tiered core and minor.
- InterVenn BiosciencescoreMulti-year partnership where Aranscia technical and laboratory resources help facilitate clinical workflows and expand availability of InterVenn's GlycoKnow Ovarian cancer diagnostic test. Aranscia suite of software solutions including Spesana and 2bPrecise provides EMR-agnostic clinical workflow utilities. AccessDx Laboratory provides logistical program support resources.
- Spartanburg Regional Healthcare System (SRHS)coreSRHS selected AccessDx Laboratory as partner to power comprehensive pharmacogenomics (PGx) program. AccessDx provides multispecialty comprehensive panels, health equity commitment through analysis of rare genetic variants, and EHR integration capabilities. PGx program launched in family practice, oncology, maternal-fetal medicine, behavioral health, and pediatrics settings. PGx insights incorporated in SRHS's deployment of 2bPrecise Enterprise.
- Neurogen BiomarkingcorePartnership where Aranscia's technical and laboratory resources deliver clinical insights and HIPAA-compliant connectivity for Neurogen's ecosystem for early detection of Mild Cognitive Impairment (MCI) and Alzheimer's Dementia. AccessDx Laboratory provides technical, operational, and analytical support for blood-based biomarker testing measuring phosphorylated tau (p-tau) 217. 2bPrecise provides EMR-agnostic clinical workflow utilities.
- PharMericaminorPanel session partnership at PointClickCare SUMMIT 2025 titled 'Advancing Care with Personalized Medication Management'. TJ Griffin, Chief Clinical Officer at PharMerica, participated as panel guest.
- HCF Management IncminorPanel session partnership at PointClickCare SUMMIT 2025 titled 'Advancing Care with Personalized Medication Management'. Jennifer Zamudio, Director of Quality at HCF Management, participated as panel guest.
- PointClickCarecoreExpanded integration with PointClickCare healthcare technology platform enables seamless delivery of pharmacogenomic risk assessments and advanced diagnostic test results. Integration allows providers to quickly identify potentially dangerous drug-gene interactions. Multi-facility analysis showed integration allowed ten facilities to identify 77% of residents at risk for severe or moderate drug-gene interactions.
- AransciacoreParent company of AccessDx Laboratory. Aranscia delivers world-class diagnostic software, services, and testing innovations. Portfolio includes 2bPrecise, AccessDx Laboratory, Spesana, and YouScript with expertise in molecular diagnostics, genomics, and digital-first clinical workflows.
- YouScriptcorePartner company providing clinical decision support software integrated with AccessDx Laboratory PGx results. YouScript knowledge base supports AccessDx PGx Profile with up-to-date scientific findings and evidence-based clinical assertions.
- 2bPrecisecorePartner company providing EMR-agnostic clinical workflow utilities. Direct integrations with 2bPrecise platform enable AccessDx PGx Profile results to auto-populate into clinical decision support tools accessible from EMRs.
Scale indicators4 records
Recent moves5 records
Expansion highlights5 records
AccessDx Laboratory competitors and assessment
Company assessmentEmerging players
- Tempus: Tempus is an AI-enabled precision medicine company combining molecular testing, clinical decision support, and data analytics. Adjacent to AccessDx's PGx-plus-CDS stack under Aranscia, and increasingly relevant in oncology where both serve DPYD and broader PGx use cases.
- Color Health: Color Health offers hereditary cancer, PGx-adjacent, and population health genetic testing with an enterprise-first model. Comparable to AccessDx in clinical genomics and the move into integrated health system partnerships and population health.
Direct peers
- Genomind: Genomind is a specialty PGx laboratory focused on mental health medication selection, most directly comparable to AccessDx's behavioral health PGx franchise. Both compete for psychiatric and primary care prescribing decisions with genetic-guided therapy recommendations.
- Natera: Natera operates molecular diagnostics across oncology, women's health, and organ health with proprietary assay technology. Comparable to AccessDx in molecular RT-PCR/multiplex capabilities and in selling complex genomic panels to enterprise healthcare customers.
- GeneDx: GeneDx is a clinical genomics laboratory with a growing hereditary cancer and rare disease menu, overlapping AccessDx's hereditary cancer panel and clinical genomics positioning. Comparable in technology (next-gen sequencing) and customer base (providers, health systems).
- Myriad Genetics: Myriad offers hereditary cancer testing (BRACAnalysis and broader panels) and has expanded into PGx-adjacent precision medicine. Highly comparable to AccessDx's hereditary cancer panel and broader PGx-oncology offerings, including DPYD testing.
Broad incumbents
- BioReference Laboratories: BioReference (an OPKO Health subsidiary) offers specialty PGx, women's health, and infectious disease testing with strong enterprise and health system positioning. Directly comparable to AccessDx in PGx and infectious disease menu and enterprise sales motion.
- Quest Diagnostics: Quest Diagnostics is the largest US clinical laboratory with nationwide logistics and a growing specialty PGx menu. Competes with AccessDx across infectious disease and pharmacogenomics at scale, particularly for enterprise health system and LTPAC contracts.
- Laboratory Corporation of America (Labcorp): Labcorp is a national full-service diagnostics provider with extensive PGx and infectious disease menus. Comparable as a broad incumbent that AccessDx competes against for provider and health system business, especially in PGx panels and DPYD testing.
Regional players
- Eurofins Viracor: Eurofins Viracor is a specialty infectious disease and immunology laboratory offering multiplex molecular panels. Comparable to AccessDx's infectious disease menu (respiratory, GI, UTI panels) and its transplant/immunology-adjacent positioning.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
AccessDx Laboratory social profiles
Digital presenceAccessDx Laboratory compliance and trust
Trust signalCompliance5 records
AccessDx Laboratory financial estimates
Financial estimateRevenue estimate
Valuation estimate
AccessDx Laboratory leadership team
Management profileNumber of profiles
Profiles4 records
AccessDx Laboratory funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
AccessDx Laboratory M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about AccessDx Laboratory
What does AccessDx Laboratory do?
AccessDx Laboratory operates as a CLIA-certified, CAP-accredited, and NYSDOH-approved molecular diagnostic laboratory delivering pharmacogenomics (PGx) testing, hereditary cancer genomics testing, and a portfolio of multiplex RT-PCR infectious disease panels (respiratory, gastrointestinal, urinary, wound, nail, COVID-19, and influenza). Testing is offered to healthcare providers through a web-based provider portal, paper requisitions, and integrations with PointClickCare, 2bPrecise, and YouScript clinical decision support.
Is AccessDx Laboratory a public or private company?
AccessDx Laboratory is a private company. It is classified as corporate owned and is currently operating.
When was AccessDx Laboratory founded?
AccessDx Laboratory was founded in 2016. It employs 251 to 500 people.
Where is AccessDx Laboratory based?
AccessDx Laboratory is headquartered in Houston, United States, in the North America region.
How does AccessDx Laboratory make money?
Two revenue lines are on record. Clinical Laboratory Testing Services are the primary driver. The others are clinical Decision Support Integration.
Who are AccessDx Laboratory's main competitors?
Emerging players on record are Tempus and Color Health. Direct peers are Genomind, Natera, GeneDx and Myriad Genetics. Broad incumbents are BioReference Laboratories, Quest Diagnostics and Laboratory Corporation of America (Labcorp). Eurofins Viracor is listed as a regional player.
Does AccessDx Laboratory have an API?
No public API is recorded for AccessDx Laboratory.
What industry is AccessDx Laboratory in?
AccessDx Laboratory's product category is Molecular Diagnostics. Its primary akta.pro industry code is HLAAANAB, Pharmacogenomics (PGx) Decision Support, with a secondary code of HLAAANAC, Companion Diagnostics (CDx) Development & Commercialization. Its NAICS code is 621511 and its SIC code is 8071.